Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2016 16:20 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing

BERKELEY HEIGHTS, N.J., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”) today announced that on February 2, 2016, the...
February 02, 2016 07:00 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral...
January 11, 2016 07:00 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016

BERKELEY HEIGHTS, N.J., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2015 achievements and provided an...
December 14, 2015 07:00 ET | Source: Bio Green Med Solution, Inc.

Molecular Basis for Development of Cyclacel’s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium

BERKELEY HEIGHTS, N.J., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation of preclinical...
November 23, 2015 07:00 ET | Source: Bio Green Med Solution, Inc.

CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

BERKELEY HEIGHTS, N.J., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation of preclinical...
November 12, 2015 16:06 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
November 09, 2015 07:00 ET | Source: Bio Green Med Solution, Inc.

Mechanistic Rationale for CYC065, Cyclacel’s CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

BERKELEY HEIGHTS, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation of preclinical...
November 05, 2015 07:00 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
October 26, 2015 16:05 ET | Source: Bio Green Med Solution, Inc.

Data to be Presented on CYC065, Cyclacel’s CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference

BERKELEY HEIGHTS, N.J., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced an upcoming presentation of...
October 22, 2015 07:00 ET | Source: Bio Green Med Solution, Inc.

Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

BERKELEY HEIGHTS, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral...